Key Highlights

  • Eli Lilly (NYSE:LLY) jumped 6.7 percent to USD 1,374.21 on October 29, 2026, after lifting 2026 Revenue guidance to USD 91 billion to 92 billion. Third-quarter revenue came in at USD 24.4 billion versus USD 22.6 billion expected, and adjusted Earnings were USD 7.48 per share.
  • Merck (NYSE:MRK) advanced about 4 percent on October 29, 2026 following earnings, with defensive and value beats helping a rotation trade, according to one account. Earnings figures were unavailable, so only the direction is confirmed.
  • According to one account, Insmed (NASDAQ:INSM) gained 16 percent on October 29, 2026, after topping revenue forecasts and lifting its full-year guidance. Revenue, earnings and guidance numbers were not accessible, so the scale of the increase remains unknown.
  • Stryker (NYSE:SYK) dropped roughly 12 percent to 13 percent after hours on October 29, 2026, once it trimmed full-year guidance to adjusted earnings of USD 14.80 to 14.90 per share, versus a USD 14.95 consensus, and organic growth of 6.5 percent to 7 percent, versus 8.2 percent expected.

Eli Lilly (NYSE:LLY): Large beat, raised revenue guide

Eli Lilly (NYSE:LLY) reported third-quarter results on October 29, 2026. Revenue of USD 24.4 billion topped the USD 22.6 billion consensus by about USD 1.8 billion, simple arithmetic on two published numbers and a gap of roughly 8 percent, while adjusted earnings of USD 7.48 per share beat an estimate of about USD 6.3. Management lifted 2026 revenue guidance to USD 91 billion to 92 billion. The shares closed up 6.7 percent at USD 1,374.21. Intraday gains of 4.4 percent to 6.7 percent appeared in different accounts depending on the timestamp, but the closing figure is 6.7 percent, and three published accounts confirm the results and the guidance. The company release remains the main check on every figure, and the Earnings Per Share guidance was lowered in that same release. The earnings outlook moved the other way. Adjusted earnings guidance was trimmed to USD 35 to 36 per share because acquired Research and Development charges of USD 4.57 per share are being counted. The charge is a one-time cost of buying future products, so the trimmed guide does not mean the current Business is earning less. Foundayo, the new obesity pill, reportedly fell short of expectations, a claim that comes from published accounts, so the size of the shortfall is not stated.

Merck (NYSE:MRK): Defensive earnings, direction only

Merck (NYSE:MRK) climbed about 4 percent on October 29, 2026 following earnings. eBay (NASDAQ:EBAY) gained 3 percent. Shell (NYSE:SHEL) rose 2.4 percent. UPS (NYSE:UPS) rose 2 percent. Defensive and value earnings beats helped fuel a rotation trade while technology sold off. The direction of each move was verified in one account per company, but the underlying earnings numbers were absent from the published accounts. A pharmaceutical group, an online marketplace, an energy major and a logistics company are not natural peers, so the shared link is the market backdrop and the tone of results rather than the business. Earnings reactions in this group were modest compared with the double-digit moves seen elsewhere in the market, which fits the defensive character of the businesses. Readers should check the earnings numbers in company releases. UPS reportedly raised its 2026 revenue guidance to USD 92.6 billion from USD 91.2 billion. Simple arithmetic puts the increase at USD 1.4 billion, or about 1.5 percent. A raise of that size is modest, which fits a gain of about 2 percent, but the figure appears in a single account and should be checked against the company release. Guidance matters because it signals whether the current trend is expected to continue.

Insmed (NASDAQ:INSM): Raised guidance, no figures

Insmed (NASDAQ:INSM) rose 16 percent on October 29, 2026 after beating revenue expectations and raising guidance. The same day, Norwegian Cruise Line climbed 13 percent after a stronger third quarter and a higher 2026 EPS guide. These are the only confirmed facts: the revenue, EPS and guidance numbers were absent from the published accounts, so this article cannot say how large either the beat or the raise was. Each direction was confirmed in a single account, a thinner standard than the two-account verification used for other names. Insmed is a biopharmaceutical company and Norwegian Cruise Line is a cruise operator, so their only link is the direction of their guidance. One strong day of trading does not make either stock a trend. Guidance is management's forecast for future results, and raising it tells investors the business is running ahead of plan. A raise can matter more than a beat alone because it resets expectations for coming quarters, and analysts revise their models accordingly. For a commercial-stage biotech such as Insmed, product sales growth drives the revenue line, while for a cruise operator, ticket pricing and onboard spending drive results. The common thread is that both companies offered a more optimistic outlook while the technology sector sold off, which may have drawn rotation flows toward companies with improving visibility.

Stryker (NYSE:SYK): Guidance cut on both lines

Stryker (NYSE:SYK) reported after the close on October 29, 2026 and lowered its full-year outlook. Adjusted earnings per share are now expected between USD 14.80 and USD 14.90, and the top of that range sits below the USD 14.95 consensus. Organic growth, which strips out acquisitions and currency, is guided at 6.5 percent to 7 percent, against 8.2 percent expected by analysts. The after-hours decline of about 12 percent to 13 percent appears in two published accounts, while the premarket figure of 11.2 percent comes from the premarket quote. Third-quarter revenue and earnings details were not retrieved here, so only the guidance figures and share moves are stated. Guidance matters because analysts value a medical device maker on expected earnings in coming quarters. When management lowers the range, forecasts get cut and the multiple investors will pay can shrink at the same time. Here the organic growth cut is the larger gap, since 6.5 percent to 7 percent sits more than half a point below 8.2 percent.

Where Things Stand

In short, healthcare earnings split by what each company said about the future, not by sub-sector alone. Lilly raised revenue guidance, Insmed raised its full-year outlook and Merck (NYSE:MRK) rose alongside defensive earners, while Stryker cut both its earnings and organic growth ranges. Gaps matter: Merck (NYSE:MRK) and Insmed figures were not available, and the Lilly obesity pill Foundayo is reported to have fallen short. The next catalysts are the October 30 open, company releases and Novo Nordisk's report on November 4, 2026. This is not Investment advice.